Accelerate Diagnostics Inc

Most Recent

• 

  .

  Company & Industry Overviews

  What Are Accelerate Diagnostics’ Key Strengths?

  In June 2017, Accelerate Diagnostics (AXDX) raised net proceeds of $83.2 million from a public offering of 2.8 million shares of common stock.

• 

  .

  Company & Industry Overviews

  Does Accelerate Diagnostics’ Financial Performance Bode Well?

  The net sales of Accelerate Diagnostics (AXDX) increased from $24,000 in 3Q16 to $828,000 in 3Q17.

• 

  .

  Company & Industry Overviews

  What’s the Competitive Landscape for Accelerate Diagnostics?

  Accelerate Diagnostics (AXDX) currently competes with companies with automated microbiological testing products on the market like Becton Dickinson (BDX), bioMerieux, Danaher (DHR), Bruker (BRKR), Luminex (LMNX), and T2 Biosystems (TTOO).

• 

  .

  Company & Industry Overviews

  What’s the Potential Market for Accelerate Diagnostics’ Products?

  Accelerate Diagnostics’ (AXDX) pheno system utilizes genotypic and phenotypic technology to identify infectious pathogens and perform antibiotic susceptibility tests.